BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Hoffmann P, Krisam J, Wehling C, Kloeters-Plachky P, Leopold Y, Belling N, Gauss A. Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease. World J Gastroenterol 2019; 25(31): 4481-4492 [PMID: 31496626 DOI: 10.3748/wjg.v25.i31.4481]
URL: https://www.wjgnet.com/1007-9327/full/v25/i31/4481.htm
Number Citing Articles
1
Elisa Proietti, Renske W M Pauwels, Christien J van der Woude, Michael Doukas, Lindsey Oudijk, Maikel P Peppelenbosch, Ursula Grohmann, Marie-Rose B S Crombag, Annemarie C de Vries, Gwenny M Fuhler. Ustekinumab Tissue and Serum Levels in Patients With Crohn’s Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After InductionInflammatory Bowel Diseases 2023; 29(7): 1038 doi: 10.1093/ibd/izac169
2
Taina Sipponen, Clas-Göran af Björkesten, Taru Hallinen, Tuire Ilus, Erkki Soini, Anja Eberl, Mikko Heikura, Mikko Kellokumpu, Ritva Koskela, Christian Nielsen, Heikki Nuutinen, Markku Heikkinen, Ulla-Maija Suhonen, Jyrki Tillonen, E. Christina M. Wennerström, Andras Borsi, Minni R. Koivunen. A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in FinlandScandinavian Journal of Gastroenterology 2021; 56(6): 661 doi: 10.1080/00365521.2021.1906315
3
Sailish Honap, Susanna Meade, Hajir Ibraheim, Peter M. Irving, Michael P. Jones, Mark A. Samaan. Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-AnalysisDigestive Diseases and Sciences 2022; 67(3): 1018 doi: 10.1007/s10620-021-06932-4
4
Diego Casas Deza, Santiago García López, Miguel Lafuente Blasco, Raquel Vicente Lidón, Juan Nerín de la Puerta, Elena Peña Gonzalez, Yolanda Ber Nieto, Mara Charro Calvillo, María José Alcalá Escriche, Fernando Gomollón García, Maite Arroyo Villarino. Eficacia y seguridad de ustekinumab en la práctica clínica real. Estudio multicéntrico retrospectivo. Cohorte ARAINFGastroenterología y Hepatología 2020; 43(3): 126 doi: 10.1016/j.gastrohep.2019.09.011
5
Antonio Tursi, Giammarco Mocci, Angelo Del Gaudio, Alfredo Papa. Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studiesExpert Opinion on Biological Therapy 2024; 24(3): 171 doi: 10.1080/14712598.2024.2316180
6
Anna Viola, Marco Muscianisi, Fabio S Macaluso, Marco Ventimiglia, Maria Cappello, Antonino C Privitera, Antonio Magnano, Dario Pluchino, Giovanni Magrì, Concetta Ferracane, Filippo Mocciaro, Serena Garufi, Enrica Giuffrida, Giuseppe Costantino, Gabriele Fiocco, Mauro Grova, Laura Guida, Angela Alibrandi, Ambrogio Orlando, Walter Fries. Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseasesJGH Open 2021; 5(3): 364 doi: 10.1002/jgh3.12502
7
Yaqing Bai, Yinghao Sun, Qi He, Xiaoyin Bai, Hong Yang. Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysisEuropean Journal of Gastroenterology & Hepatology 2024; 36(4): 359 doi: 10.1097/MEG.0000000000002718
8
Motohiro Esaki, Yutaro Ihara, Naoyuki Tominaga, Hironobu Takedomi, Nanae Tsuruoka, Takashi Akutagawa, Takahiro Yukimoto, Keisuke Kawasaki, Junji Umeno, Takehiro Torisu, Yasuhisa Sakata. Predictive factors of the clinical efficacy of ustekinumab in patients with refractory Crohn’s disease: tertiary centers experience in JapanInternational Journal of Colorectal Disease 2023; 38(1) doi: 10.1007/s00384-023-04359-z
9
Haixia Ren, Jian Kang, Jing Wang, Juan Su, Liping Zou, Anning Yin, Jiao Li, Qian Zhou, Wei Wang, Zhishun Tang, Jing Zhang, Yueyue Lu, Yuanping Yang, Chengen Qiu, Yijuan Ding, Weiguo Dong, Ping An. Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn’s DiseaseInflammatory Bowel Diseases 2023;  doi: 10.1093/ibd/izad184
10
Tatjana Hoffmann, Stefano Fusco, Gunnar Blumenstock, Saman Sadik, Nisar P Malek, Eckhart Froehlich. Evaluation of bowel wall thickness by ultrasound as early diagnostic tool for therapeutic response in Crohn’s disease patients treated with ustekinumabZeitschrift für Gastroenterologie 2022; 60(08): 1212 doi: 10.1055/a-1283-6550
11
Jing Wang, Hong Liu, Yadan Wang, Jing Wu, Canghai Wang, Kuiliang Liu, Qin Qin. The Polymorphisms of Interleukin-12B Gene and Susceptibility to Inflammatory Bowel Diseases: A Meta-analysis and Trial Sequential AnalysisImmunological Investigations 2021; 50(8): 987 doi: 10.1080/08820139.2020.1863981
12
He Zhou, Fang Wang, Jian Wan, Song Su, Yanting Shi, Xiaofei Li, Tong Wu, Jie Liang. Systematic Review and Meta-Analysis of Observational Studies on the Effectiveness and Safety of Ustekinumab among Patients with Inflammatory Bowel Disease in Eastern and Western CountriesJournal of Clinical Medicine 2023; 12(5): 1894 doi: 10.3390/jcm12051894
13
Luc Manlay, Gilles Boschetti, Bruno Pereira, Bernard Flourié, Michel Dapoigny, Maud Reymond, Elisa Sollelis, Claire Gay, Mathilde Boube, Anthony Buisson, Stéphane Nancey. Comparison of short‐ and long‐term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor therapyAlimentary Pharmacology & Therapeutics 2021; 53(12): 1289 doi: 10.1111/apt.16377
14
UstekinumabReactions Weekly 2019; 1774(1): 301 doi: 10.1007/s40278-019-68747-0
15
Giammarco Mocci, Antonio Tursi, Francesca Maria Onidi, Paolo Usai-Satta, Giovanni Mario Pes, Maria Pina Dore. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving ParadigmsJournal of Clinical Medicine 2024; 13(5): 1519 doi: 10.3390/jcm13051519
16
Cristina Rubín de Célix, María Chaparro, Javier P. Gisbert. Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational StudiesJournal of Clinical Medicine 2022; 11(14): 4202 doi: 10.3390/jcm11144202
17
Ferhat Bacaksız, Derya Arı, Volkan Gökbulut, Ömer Öztürk, Ertuğrul Kayaçetin. One-year real life data of our patients with moderate-severe Crohn’s disease who underwent ustekinumab therapyScottish Medical Journal 2021; 66(3): 152 doi: 10.1177/00369330211008587
18
Ana Gutiérrez, Iago Rodríguez-Lago. How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World DataFrontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.640813
19
Johan F K F Ilvemark, Tawnya Hansen, Thomas M Goodsall, Jakob B Seidelin, Heba Al- Farhan, Mariangela Allocca, Jakob Begun, Robert V Bryant, Dan Carter, Britt Christensen, Marla C Dubinsky, Krisztina B Gecse, Torsten Kucharzik, Cathy Lu, Christian Maaser, Giovanni Maconi, Kim Nylund, Carolina Palmela, Stephanie R Wilson, Kerri Novak, Rune Wilkens. Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus StatementJournal of Crohn's and Colitis 2022; 16(4): 554 doi: 10.1093/ecco-jcc/jjab173
20
Laura Lorenzo González, Teresa Valdés Delgado , Juan María Vázquez Morón, Luisa Castro Laria, Eduardo Leo Carnerero, María Belén Maldonado Pérez, Damián Sánchez Capilla, Héctor Pallarés Manrique, Antonia Sáez Díaz, Federico Argüelles Arias. Ustekinumab in Crohn's disease: real-world outcomes and predictors of response.Revista Española de Enfermedades Digestivas 2020;  doi: 10.17235/reed.2020.7352/2020
21
Marisa Iborra, Belén Beltrán, Agnes Fernández‐Clotet, Eva Iglesias‐Flores, Pablo Navarro, Montserrat Rivero, Ana Gutiérrez, Mónica Sierra‐Ausin, Francisco Mesonero, Rocío Ferreiro‐Iglesias, Joaquín Hinojosa, Xavier Calvet, Beatriz Sicilia, Carlos González‐Muñoza, Beatriz Antolín, María González‐Vivo, Ana Y. Carbajo, Santiago García‐López, Albert Martín‐Cardona, Gerard Surís, María Dolores Martin‐Arranz, Ruth de Francisco, Fiorella Cañete, Eugeni Domènech, Pilar Nos. Real‐world long‐term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registryAlimentary Pharmacology & Therapeutics 2020; 52(6): 1017 doi: 10.1111/apt.15958
22
Diego Casas Deza, Santiago García López, Miguel Lafuente Blasco, Raquel Vicente Lidón, Juan Nerín de la Puerta, Elena Peña Gonzalez, Yolanda Ber Nieto, Mara Charro Calvillo, María José Alcalá Escriche, Fernando Gomollón García, Maite Arroyo Villarino. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohortGastroenterología y Hepatología (English Edition) 2020; 43(3): 126 doi: 10.1016/j.gastre.2019.09.010
23
Choong Wui Cho, Myung-Won You, Chi Hyuk Oh, Chang Kyun Lee, Sung Kyoung Moon. Long-term Disease Course of Crohn’s Disease: Changes in Disease Location, Phenotype, Activities, and Predictive FactorsGut and Liver 2022; 16(2): 157 doi: 10.5009/gnl210118
24
Uni Wong, Raymond K Cross. Emerging drugs for the treatment of inflammatory bowel diseaseExpert Opinion on Emerging Drugs 2022; 27(4): 369 doi: 10.1080/14728214.2022.2147507
25
Clas-Göran af Björkesten, Tuire Ilus, Taru Hallinen, Erkki Soini, Anja Eberl, Kalle Hakala, Mikko Heikura, Airi Jussila, Ritva Koskela, Inka Koskinen, Veikko Moilanen, Christian Nielsen, Urpo Nieminen, Heikki Nuutinen, Markku Heikkinen, Ulla-Maija Suhonen, Jyrki Tillonen, Karri Utriainen, Ilkka Vihriälä, Christina Wennerström, Andras Borsi, Riikka Nissinen, Minni R. Koivunen, Taina Sipponen. Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohortEuropean Journal of Gastroenterology & Hepatology 2020; 32(12): 1507 doi: 10.1097/MEG.0000000000001831
26
L. Monin, S. Dubois, C. Reenaers, C. Van Kemseke, P. Latour, D. Van Daele, S Vieujean, L. Seidel, E. Louis. Ustekinumab in bio-naïve and bio-failure Crohn's disease patients: Results from a « real-life » monocentric cohort.Digestive and Liver Disease 2021; 53(1): 72 doi: 10.1016/j.dld.2020.10.040
27
Cassandra Rayer, Maria Nachury, Arnaud Bourreille, Xavier Roblin, Laurent Peyrin-Biroulet, Stephanie Viennot, Mathurin Flamant, David Laharie, Bénédicte Caron, Marie Dewitte, Laurent Siproudhis, Mathurin Fumery, Guillaume Bouguen. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective studyBMC Gastroenterology 2022; 22(1) doi: 10.1186/s12876-022-02583-5
28
Pepijn W.A. Thomas, Mark van Caem, Rachel L. West, Maurice G.V.M Russel, Jeroen M. Jansen, Tessa E.H. Römkens, Frank Hoentjen. Long-term effectiveness and safety of ustekinumab in Crohn’s disease: a prospective cohort studyEuropean Journal of Gastroenterology & Hepatology 2023; 35(3): 261 doi: 10.1097/MEG.0000000000002506
29
Hadrien Alric, Aurélien Amiot, Julien Kirchgesner, Xavier Tréton, Matthieu Allez, Yoram Bouhnik, Laurent Beaugerie, Franck Carbonnel, Antoine Meyer. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factorAlimentary Pharmacology & Therapeutics 2020; 51(10): 948 doi: 10.1111/apt.15706
30
Hongsheng Yang, Bingyang Li, Qin Guo, Jian Tang, Bo Peng, Ni Ding, Miao Li, Qingfang Yang, Zicheng Huang, Na Diao, Xia Zhu, Jun Deng, Huili Guo, Pinjin Hu, Kang Chao, Xiang Gao. Systematic review with meta‐analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseasesAlimentary Pharmacology & Therapeutics 2022; 55(7): 764 doi: 10.1111/apt.16802
31
O.V. Knyazev, O.B. Schukina, A.V. Kagramanova, A.A. Lishchinskaya, I.A. Li, E.A. Sabelnikova, B.A. Nanaeva, M.Yu. Timanovskaya, T.A. Kosacheva, N.A. Fadeeva, K.A. Nikolskaya, E.Yu. Zhulina, N.V. Kamzarakova, A.I. Parfenov. Real-world effectiveness of ustekinumab in maintenance therapy for Crohn´s diseaseDokazatel'naya gastroenterologiya 2023; 12(3): 29 doi: 10.17116/dokgastro20231203129
32
Ariella Bar‐Gil Shitrit, Ami Ben‐Ya’acov, Matan Siterman, Matti Waterman, Ayal Hirsh, Doron Schwartz, Eran Zittan, Yehonatan Adler, Benjamin Koslowsky, Irit Avni‐Biron, Yehuda Chowers, Yulia Ron, Eran Israeli, Bella Ungar, Henit Yanai, Nitsan Maharshak, Shomron Ben‐Horin, Rami Eliakim, Iris Dotan, Eran Goldin, Uri Kopylov. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn’s disease: A multicenter Israeli studyUnited European Gastroenterology Journal 2020; 8(4): 418 doi: 10.1177/2050640620902956
33
Saskia Inniss, Konstantinos C. Fragkos, Lisa Whitley, Rachel Wimpory, Eleanor Rebello, Ana Lisboa, Tanvi Khetan, Jasmine Hassan, Kate Simpson, Anisha Bhagwanani, Roser Vega, Ioanna Parisi, Paul Harrow, Edward Seward, Sara McCartney, Stuart Bloom, Andrew M. Smith, Andrew Plumb, Farooq Z. Rahman. Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn’s disease cohort with penetrating disease, -ostomies and sarcopeniaTherapeutic Advances in Chronic Disease 2023; 14 doi: 10.1177/20406223231189072